These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9636505)

  • 21. Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile.
    Woodside KJ; Nichols SD; Hunter GC; Gugliuzza KK; Daller JA
    Transplant Proc; 2005 May; 37(4):1877-9. PubMed ID: 15919491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report.
    Jurewicz WA
    Transplant Proc; 1999 Nov; 31(7A):64S-66S. PubMed ID: 10576048
    [No Abstract]   [Full Text] [Related]  

  • 23. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile.
    Dahm F; Weber M; Clavien PA
    Am J Transplant; 2004 Dec; 4(12):2139; author reply 2140. PubMed ID: 15575921
    [No Abstract]   [Full Text] [Related]  

  • 24. Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral.
    Chu SH; Pang ST; Chiang YJ; Chuang CK; Chen HW; Chen CS; Chou CC; Huang CC
    Transplant Proc; 1998 Nov; 30(7):3521-3. PubMed ID: 9838543
    [No Abstract]   [Full Text] [Related]  

  • 25. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients.
    Kanbay M; Akcay A; Huddam B; Usluogullari CA; Arat Z; Ozdemir FN; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3119-20. PubMed ID: 16213325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up.
    Citterio F; Scatà MC; Romagnoli J; Pozzetto U; Nanni G; Castagneto M
    Transplant Proc; 2002 Aug; 34(5):1685-6. PubMed ID: 12176535
    [No Abstract]   [Full Text] [Related]  

  • 27. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy.
    Videla CO
    Transplant Proc; 2009; 41(6):2659-63. PubMed ID: 19715995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects.
    Margreiter R; Pohanka E; Sparacino V; Sperschneider H; Kunzendorf U; Huber W; Lameire N; Andreucci VE; Donati D; Heemann U;
    Transpl Int; 2005 Jul; 18(7):816-23. PubMed ID: 15948861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tacrolimus (FK 506) in kidney transplantation.
    Vanrenterghem Y
    Transplant Proc; 1998 Aug; 30(5):2171-3. PubMed ID: 9723431
    [No Abstract]   [Full Text] [Related]  

  • 30. Conversion from cyclosporine to tacrolimus in renal transplant recipients with gum hyperplasia.
    Kohnle M; Lütkes P; Zimmermann U; Philipp T; Heemann U
    Transplant Proc; 1999 Nov; 31(7A):44S-45S. PubMed ID: 10576043
    [No Abstract]   [Full Text] [Related]  

  • 31. Impact of tacrolimus on hyperlipidemia after renal transplantation: a Japanese single center experience.
    Manu M; Tanabe K; Tokumoto T; Ishikawa N; Shimizu T; Okuda H; Ito S; Shimmura H; Inui M; Harano M; Shiroyanagi Y; Yagisawa T; Fuchinoue S; Toma H
    Transplant Proc; 2000 Nov; 32(7):1736-8. PubMed ID: 11119912
    [No Abstract]   [Full Text] [Related]  

  • 32. Conversion from cyclosporine to tacrolimus in renal allograft recipients with delayed graft function from severe acute tubular necrosis.
    Jang HJ; Kim SC; Han DJ
    Transplant Proc; 2000 Nov; 32(7):1714-5. PubMed ID: 11119904
    [No Abstract]   [Full Text] [Related]  

  • 33. Rescue therapy with tacrolimus in renal graft patients with cyclosporine A-induced hepatotoxicity: a preliminary study.
    Yuan QS; Zheng FL; Sun Y; Yu Y; Li Y
    Transplant Proc; 2000 Nov; 32(7):1694-5. PubMed ID: 11119896
    [No Abstract]   [Full Text] [Related]  

  • 34. Histopathologic findings in routine biopsies of renal transplant allografts.
    Toki K; Kyo M; Takahara S; Hatori M; Morozumi K; Ichimaru N; Wang JD; Ding XQ; Miyamoto M; Oka K; Kyakuno M; Kojima Y; Kokado Y; Okuyama A
    Transplant Proc; 1999 Sep; 31(6):2655-8. PubMed ID: 10500759
    [No Abstract]   [Full Text] [Related]  

  • 35. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients.
    Claesson K; Mayer AD; Squifflet JP; Grabensee B; Eigler FW; Behrend M; Vanrenterghem Y; van Hooff J; Morales JM; Johnson RW; Buchholz B; Land W; Forsythe JL; Neumayer HH; Ericzon BG; Mühlbacher F
    Transplant Proc; 1998 Jun; 30(4):1292-4. PubMed ID: 9636524
    [No Abstract]   [Full Text] [Related]  

  • 36. Tacrolimus versus cyclosporine as primary prophylactic therapy after cadaveric renal transplant: two-year survival study.
    Wong KM; Cheung CY; Chan YH; Chak WL; Choi KS; Chau KF; Li CS
    Transplant Proc; 2000 Nov; 32(7):1721-2. PubMed ID: 11119907
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment.
    Abendroth D; Buchholz B; Land W; May G; Wiesel M; Färber L; Korn A; Maibücher A
    Transplant Proc; 1997; 29(1-2):275-6. PubMed ID: 9122993
    [No Abstract]   [Full Text] [Related]  

  • 38. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity.
    Diekmann F; Waiser J; Fritsche L; Dragun D; Neumayer HH; Budde K
    Transplant Proc; 2001; 33(7-8):3234-5. PubMed ID: 11750386
    [No Abstract]   [Full Text] [Related]  

  • 39. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection.
    Boratyńska M; Banasik M; Patrzałek D; Klinger M
    Ann Transplant; 2006; 11(2):51-6. PubMed ID: 17494290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients.
    Pohanka E; Margreiter R; Sparacino V; Sperschneider H;
    Transplant Proc; 2005 May; 37(4):1874-6. PubMed ID: 15919490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.